

Council of the European Union

> Brussels, 28 May 2024 (OR. en)

10225/24

Interinstitutional File: 2024/0021(COD)

> CODEC 1331 SAN 302 PHARM 78 MI 530 COMPET 585

'I/A' ITEM NOTE

| From: | General Secretariat of the Council |
|----------|--|
| To: | Permanent Representatives Committee/Council |
| Subject: | Draft REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards a gradual roll-out of Eudamed, the obligation to inform in case of interruption or discontinuation of supply, and transitional provisions for certain <i>in vitro</i> diagnostic medical devices (first reading) - Adoption of the legislative act |

- On 23 January 2024 the <u>Commission</u> submitted its proposal¹, based on Article 114 and Article 168(4), point (c), TFEU, to the Council.
- 2. The European Economic and Social Committee delivered its opinion on 20 March 2024².
- 3. The <u>Committee of the Regions</u> was consulted and decided not to issue an opinion.
- 4. On 25 April 2024 the <u>European Parliament</u> adopted its position at first reading on the Commission proposal³. The outcome of voting in the European Parliament reflects the compromise agreement reached between the institutions and should, therefore, be acceptable to the Council.

¹ 5712/24.

² 8102/24.

³ 9237/24.

- The <u>Permanent Representatives Committee</u> is therefore asked to confirm its agreement and to suggest that the <u>Council</u> approve the European Parliament's position, as set out in PE-CONS 54/24 + COR 1, as an "A" item at a forthcoming meeting.
- 6. If the <u>Council</u> approves the European Parliament's position, the legislative act will be adopted.

After being signed by the Presidents of the European Parliament and of the Council, the legislative act will be published in the *Official Journal of the European Union*.